CellCentric

The company's lead product is Inobrodib (formerly CCS1477), a first-in-class, orally administered small molecule inhibitor of p300/CBP. Inobrodib is designed to disrupt the growth of cancer cells by impacting the expression of key cancer-driving genes like MYC and IRF4. A primary advantage of the drug is its oral capsule formulation, which allows for at-home administration, a significant preference for patients that can improve access and quality of life. CellCentric's business model is centered on advancing Inobrodib through clinical trials to secure regulatory approval and eventual commercialization, either independently or through licensing deals. An earlier program was licensed to Takeda Pharmaceuticals. The company collaborates extensively with academic research groups and contract research organizations (CROs) to conduct its R&D.

CellCentric is primarily targeting hematological malignancies and solid tumors. Its main focus is on relapsed and refractory multiple myeloma, a difficult-to-treat blood cancer where many patients eventually stop responding to existing therapies. Clinical trials have shown promising efficacy and a manageable safety profile for Inobrodib, particularly when used in combination with other standard-of-care drugs. The U.S. FDA has granted both Fast Track and Orphan Drug designations to Inobrodib for this indication. The company has secured significant funding to advance its clinical programs, including a $120 million Series C round in May 2025, with investors including RA Capital Management, Forbion, Pfizer, and BrightEdge, the venture arm of the American Cancer Society. These funds are earmarked for a pivotal Phase II/III study with the potential for accelerated approval and to support further combination trials.